Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. HCAT
stocks logo

HCAT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
73.97M
-7.08%
0.104
+159.73%
74.21M
-6.55%
0.082
+716.7%
75.40M
-6.6%
0.090
+125%
Estimates Revision
The market is revising Downward the revenue expectations for Health Catalyst, Inc. (HCAT) for FY2025, with the revenue forecasts being adjusted by -1.24% over the past three months. During the same period, the stock price has changed by -20.41%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-21.49%
In Past 3 Month
Stock Price
Go Down
down Image
-20.41%
In Past 3 Month
Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 2.690
sliders
Low
3.00
Averages
4.00
High
5.00
Current: 2.690
sliders
Low
3.00
Averages
4.00
High
5.00
Wells Fargo
Stan Berenshteyn
Equal Weight
downgrade
$6 -> $5
2025-11-11
Reason
Wells Fargo
Stan Berenshteyn
Price Target
$6 -> $5
2025-11-11
downgrade
Equal Weight
Reason
Wells Fargo analyst Stan Berenshteyn lowered the firm's price target on Health Catalyst to $5 from $6 and keeps an Equal Weight rating on the shares. The firm notes that Q3 slightly beat on one-offs, while 2025 was reaffirmed. Wells is "a bit more cautious" on 2026 EBITDA, but still sees meaningful progression.
Stifel
David Grossman
Hold
downgrade
2025-11-11
Reason
Stifel
David Grossman
Price Target
2025-11-11
downgrade
Hold
Reason
Stifel analyst David Grossman lowered the firm's price target on Health Catalyst to $3.75 from $4.50 and keeps a Hold rating on the shares after a "modest" Q3 revenue and EBITDA beat along with 2025 guidance being maintained. The absence of near-term catalysts is reflected in the multiple, but actions repositioning the business for growth and margin expansion create a potential opportunity for "those with longer-term perspective," the analyst tells investors.
Citi
Daniel Grosslight
Neutral
downgrade
2025-11-11
Reason
Citi
Daniel Grosslight
Price Target
2025-11-11
downgrade
Neutral
Reason
Citi analyst Daniel Grosslight lowered the firm's price target on Health Catalyst to $3.25 from $3.50 and keeps a Neutral rating on the shares.
Canaccord
Richard Close
Buy
downgrade
$9 -> $5
2025-08-29
Reason
Canaccord
Richard Close
Price Target
$9 -> $5
2025-08-29
downgrade
Buy
Reason
Canaccord analyst Richard Close lowered the firm's price target on Health Catalyst to $5 from $9 and keeps a Buy rating on the shares. The firm updated its model following Q2 results and following the company's annual Health Analytics Summit they walked away from their time with management and clients encouraged by the direction Health Catalyst is heading. That is, shifting the business to high-margin technology and less reliance on lower-margin Professional services as AI technology is more heavily integrated into the company's offerings.
Piper Sandler
Overweight -> Neutral
downgrade
$8 -> $4
2025-08-27
Reason
Piper Sandler
Price Target
$8 -> $4
2025-08-27
downgrade
Overweight -> Neutral
Reason
Piper Sandler downgraded Health Catalyst to Neutral from Overweight with a price target of $4, down from $8. The company's bookings disappointed in the first half of 2025 and its cut revenue guidance for the remaining of the year on lower net revenue retention and churn, the analyst tells investors in a research note. The firm says Health Catalyst's 2025 guide-down removes all organic growth from the outlook while the company sees revenue declining year-over-year in 2026. Piper expects the shares to be range bound given the lack of organic growth.
Wells Fargo
Overweight
downgrade
$10 -> $6
2025-08-11
Reason
Wells Fargo
Price Target
$10 -> $6
2025-08-11
downgrade
Overweight
Reason
Wells Fargo lowered the firm's price target on Health Catalyst to $6 from $10 and keeps an Overweight rating on the shares. The firm sees top-line pressure as largely margin-neutral, and notes that cut revenue is either low-margin or offset by cost savings. Wells' adjusted EBITDA outlook is essentially unchanged.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Health Catalyst Inc (HCAT.O) is 7.50, compared to its 5-year average forward P/E of -27.35. For a more detailed relative valuation and DCF analysis to assess Health Catalyst Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-27.35
Current PE
7.50
Overvalued PE
88.33
Undervalued PE
-143.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-89.64
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
66.76
Undervalued EV/EBITDA
-246.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.47
Current PS
0.00
Overvalued PS
6.64
Undervalued PS
0.30
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

HCAT News & Events

Events Timeline

(ET)
2025-11-10
16:22:30
Health Catalyst supports FY25 revenue projection of $310M, slightly below consensus of $312.1M.
select
2025-11-10
16:21:14
Health Catalyst reports Q4 revenue of $73.5M, falling short of consensus estimate of $74.79M.
select
2025-11-10
16:20:35
Health Catalyst announces Q3 adjusted EPS of 6 cents, falling short of consensus estimate of 7 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02PRnewswire
Health Catalyst Appoints First Light CEO Matt Arens to Board, Holding 19% Stake
  • New Board Member: Health Catalyst announced the appointment of Matt Arens, CEO of First Light, to its board effective December 1, 2025, with First Light being the largest shareholder holding approximately 19% of shares, which is expected to bring valuable capital market experience to enhance shareholder value.
  • Shareholder Value Creation: With over 30 years in the investment field, Arens focuses on identifying growth opportunities in healthcare companies, and his addition is anticipated to sharpen Health Catalyst's strategic focus in healthcare data analytics, enabling measurable healthcare improvements.
  • Leadership Transition: Current board member Matthew Kolb will not seek re-election, which is expected to create more room for new members, enhancing the board's diversity and expertise, thereby furthering the company's strategic objectives.
  • Market Potential: Arens stated that the market is not fully recognizing the embedded value within Health Catalyst, and with a low EBITDA multiple and high free cash flow potential, significant appreciation in the company's shares is expected, boosting investor confidence.
[object Object]
Preview
5.0
12-02Newsfilter
Health Catalyst Appoints First Light Founder Matt Arens to Board, Holding 19% Shares
  • New Board Member: Health Catalyst announced the appointment of Matt Arens, founder of First Light, to its board, with Arens and his firm holding approximately 13.9 million shares, or about 19% of the company, which is expected to bring deep capital market experience to the company.
  • Shareholder Value Enhancement: Arens's investment experience in the healthcare sector will assist Health Catalyst in identifying and creating significant shareholder value, advancing the company's strategic goals in data-driven healthcare improvement.
  • Leadership Transition: Current director Matthew Kolb will not stand for re-election, which is expected to provide greater development space for new members and further drive the board's strategic direction.
  • Market Potential: Arens noted that the market has not fully recognized the embedded value within Health Catalyst, and combined with a low EBITDA multiple and high free cash flow generation potential, indicates significant appreciation opportunities for the company's shares.
[object Object]
Preview
1.0
11-15Newsfilter
Health Catalyst to Attend Upcoming Investor Conferences

  • Upcoming Investor Conferences: Health Catalyst, Inc. will participate in several investor conferences, including the Stephens Annual Investment Conference on November 19, 2025, and the Canaccord Genuity MedTech Forum on November 20, 2025, featuring key executives in discussions and meetings.

  • Company Overview: Health Catalyst is a leading provider of data and analytics technology for healthcare organizations, with over 1,100 clients relying on its solutions to drive clinical, financial, and operational improvements.

  • Technology and Services: The company offers a cloud-based technology ecosystem, Health Catalyst Ignite™, which utilizes AI-enabled data analytics to transform complex healthcare information into actionable insights.

  • Proven Impact: Health Catalyst has a multi-decade mission focused on delivering measurable results, claiming to have generated billions of dollars in improvements across healthcare systems worldwide.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Health Catalyst Inc (HCAT) stock price today?

The current price of HCAT is 2.69 USD — it has decreased -1.1 % in the last trading day.

arrow icon

What is Health Catalyst Inc (HCAT)'s business?

Health Catalyst, Inc. is a provider of data and analytics technology and services to healthcare organizations. The Company's solution comprises its cloud-based data platform, applications, and expertise. Its segments include Technology and Professional Services. The Technology segment includes its data platform, analytics applications and support services and earns primarily from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees. The Professional Services segment is generally a combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver capabilities to its clients to fully configure and utilize the benefits of its technology offerings. Its clients, which are primarily healthcare providers, use its Solution to manage their data, derive analytical insights to operate their organization, and produce measurable clinical, financial, and operational improvements.

arrow icon

What is the price predicton of HCAT Stock?

Wall Street analysts forecast HCAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCAT is 4.00 USD with a low forecast of 3.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Health Catalyst Inc (HCAT)'s revenue for the last quarter?

Health Catalyst Inc revenue for the last quarter amounts to 76.32M USD, decreased -0.04 % YoY.

arrow icon

What is Health Catalyst Inc (HCAT)'s earnings per share (EPS) for the last quarter?

Health Catalyst Inc. EPS for the last quarter amounts to -0.32 USD, increased 33.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Health Catalyst Inc (HCAT)'s fundamentals?

The market is revising Downward the revenue expectations for Health Catalyst, Inc. (HCAT) for FY2025, with the revenue forecasts being adjusted by -1.24% over the past three months. During the same period, the stock price has changed by -20.41%.
arrow icon

How many employees does Health Catalyst Inc (HCAT). have?

Health Catalyst Inc (HCAT) has 1300 emplpoyees as of December 05 2025.

arrow icon

What is Health Catalyst Inc (HCAT) market cap?

Today HCAT has the market capitalization of 190.27M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free